EN | UA
EN | UA

Help Support

Back

Lubiprostone therapy in pediatric functional constipation: A comparative study with conventional laxatives

Functional constipation Functional constipation
Functional constipation Functional constipation

This randomized controlled trial examined Lubiprostone's effectiveness and safety in tackling pediatric functional constipation.

See All

Key take away

Using Lubiprostone is an effective, safe, and well-tolerated strategy for childhood and adolescent functional constipation. Its positive effects are sustained even after treatment discontinuation.

Background

This randomized controlled trial examined Lubiprostone's effectiveness and safety in tackling pediatric functional constipation.

Method

This study, conducted as a single-blinded study, incorporated 280 subjects aged 8-18 with functional constipation. Participants (adolescents and children) were randomly segregated to receive either a weight-based dose of Lubiprostone (n = 140) or conventional laxatives (n = 140) such as sodium picosulfate, bisacodyl, or lactulose for a duration of twelve weeks. This was followed by a 4-week post-observation period.

Result

Remarkable improvements were witnessed in constipation among patients in the Lubiprostone group, as opposed to the conventional therapy group (p < 0.001), as depicted in Table 1 below:

This betterment was sustained even after the discontinuation of therapy. Additionally, one-quarter of patients in the Lubiprostone group had their first spontaneous bowel movement within 48 hours of commencing the medication. Throughout the last four weeks of therapy and the four-week follow-up period, 75.7% of the Lubiprostone group maintained a Bristol stool form of 3 or 4, compared to 35.7% in the conventional therapy group (p < 0.001).

No severe adverse reactions to Lubiprostone were documented. Also, there were no instances of treatment discontinuation owing to adverse effects. In the Lubiprostone group, the most common side effects were mild and self-limiting headache and colicky abdominal pain.

Conclusion

Lubiprostone proved to be an efficient, safe, and well-tolerated pharmacotherapy for pediatric functional constipation, suggesting a potential shift in the approach to managing this ailment in younger age groups.

Source:

Journal of Pediatric Gastroenterology and Nutrition

Article:

Efficacy of lubiprostone for functional constipation treatment in adolescents and children: Randomized controlled trial

Authors:

Engy S Elkaragy et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: